Protalix BioTherapeutics
PLX
$1.13
Share price
-0.88%
Change (1 day)
-47.20%
Change (1 year)
Categories
Protalix BioTherapeutics (PLX) - Total debt
Total debt on the balance sheet as of March 2024 : $26.37 M
According to Protalix BioTherapeutics 's latest financial reports the company's total debt is $26.37 M. A company’s total debt is the sum of all current and non-current debts.
Protalix BioTherapeutics - Total debt on balance sheet (from 2011 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $26.28 M | -21.49% |
| 2022-12-31 | $33.47 M | 0.01% |
| 2021-12-31 | $33.47 M | -48.03% |
| 2020-12-31 | $64.4 M | 5.7% |
| 2019-12-31 | $60.92 M | 27.02% |
| 2018-12-31 | $47.96 M | -8.09% |
| 2017-12-31 | $52.18 M | -28.72% |
| 2016-12-31 | $73.21 M | 1.55% |
| 2015-12-31 | $72.09 M | 7.05% |
| 2014-12-31 | $67.35 M | 0.45% |
| 2013-12-31 | $67.04 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $68.70 B | 260,433.90% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $0.51 B | 1,841.07% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | $0.44 B | 1,585.47% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $19.93 B | 75,502.91% | 🇮🇱 Israel |